Exact Sciences (EXAS)
(Delayed Data from NSDQ)
$69.80 USD
+0.87 (1.26%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $69.80 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$69.80 USD
+0.87 (1.26%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $69.80 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth F Momentum D VGM
Zacks News
Exact Sciences (EXAS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed the most recent trading day at $94.56, moving +1.37% from the previous trading session.
Exact Sciences (EXAS) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed the most recent trading day at $87.93, moving -1.83% from the previous trading session.
Exact Sciences, GameStop, Intel, Intuitive Surgical and Skyworks highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Exact Sciences, GameStop, Intel, Intuitive Surgical and Skyworks highlighted as Zacks Bull and Bear of the Day
What's in Store for IDEXX Laboratories' (IDXX) Q4 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) is likely to report strong earnings for Q4, courtesy of a global surge in CAG Diagnostic revenues.
Can Critical Care Aid Edwards Lifesciences (EW) Q4 Earnings?
by Zacks Equity Research
Robust customer adoption of the HemoSphere all-in-one monitoring platform is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.
Bull of the Day: Exact Sciences (EXAS)
by Kevin Cook
Massive growth in Cologuard may be slowing but cancer detection is their game and multiple targets are in sight
Will New Buyouts Aid Quest Diagnostics (DGX) Q4 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) acquisition of Clinical Laboratory Services of Boston Clinical Laboratories is expected to have been accretive to its Q4 earnings.
Will Segmental Growth Aid Hologic (HOLX) in Q1 Earnings?
by Zacks Equity Research
Strength in segmental businesses is likely to have aided Hologic's (HOLX) performance in first-quarter fiscal 2020.
What's in Store for Align Technology's (ALGN) Q4 Earnings?
by Zacks Equity Research
Align Technology (ALGN) is expected to have gained from continued adoption of Invisalign system in Q4.
Can Abbott (ABT) Q4 Earnings Ride on Growth in All Lines?
by Zacks Equity Research
Abbott's (ABT) imminent quarterly results are expected to reflect a solid performance by the Established Pharmaceuticals Division (EPD) business alike the last reported quarter.
Exact Sciences (EXAS) Provides Q4 Expectations, Stock Falls
by Zacks Equity Research
Exact Sciences (EXAS) revenue growth will likely beat expectations for both the fourth quarter and 2019.
Novavax Rises on Fast Track Designation to Influenza Vaccine
by Zacks Equity Research
The FDA bestows a Fast Track Designation on Novavax's (NVAX) influenza vaccine candidate NanoFlu for adults aged 65 years and older. Shares rally.
Perrigo (PRGO) Rises on Stellar Q419 Preliminary Results
by Zacks Equity Research
Perrigo (PRGO) announces better-than-expected preliminary results for fourth-quarter 2019 as well as the full year. Shares gain.
Can Focus on High-Growth Area Up OrganiGram (OGI) Q1 Earnings?
by Zacks Equity Research
OrganiGram (OGI) is expected to have benefited from its firm focus on building brand equity and ongoing product innovation in the fiscal first quarter.
Can Focus on High-Growth Area Up OrganiGram (OGI) Q1 Earnings?
by Zacks Equity Research
OrganiGram (OGI) is expected to have benefited from its firm focus on building brand equity and ongoing product innovation in the fiscal first quarter.
Has Exact Sciences (EXAS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (EXAS) Outperforming Other Medical Stocks This Year?
Can New Strategic Efforts Aid Apharia's (APHA) Q2 Earnings?
by Zacks Equity Research
Apharia (APHA) is successfully running its global cannabis business with more than 1,200 team members globally.
Can Cannabis Therapy Drive Aphria's (APHA) Q2 Earnings?
by Zacks Equity Research
Aphria (APHA) expects to deliver strong second-quarter fiscal 2020 results banking on solid performance of its cannabis therapy business.
Top Ranked Momentum Stocks to Buy for January 13th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 13th
Exact Sciences Rides on Cologuard, Eyes Merger Synergies
by Zacks Equity Research
Exact Sciences (EXAS) continues to make a notable progress with its Cologuard business.
Walgreens Boots (WBA) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Higher comparable pharmacy sales and expanded comparable prescription volume are likely to have aided growth in Walgreens Boots' (WBA) Retail Pharmacy USA during the first quarter of fiscal 2020.
Has Exact Sciences (EXAS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (EXAS) Outperforming Other Medical Stocks This Year?
Medtronic (MDT) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
In the fiscal second quarter, Medtronic (MDT) is expected to have registered strong growth in its ICD and CRT product lines.
Exact Sciences (EXAS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 24.39% and 1.54%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Exact Sciences (EXAS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Exact Sciences (EXAS) closed at $89.89, marking a +1.02% move from the previous day.